Fig. 2: Antibody responses of HCWs after receiving one and two doses of COVID-19 vaccines with a long vaccine dose interval. | Nature Communications

Fig. 2: Antibody responses of HCWs after receiving one and two doses of COVID-19 vaccines with a long vaccine dose interval.

From: Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants

Fig. 2

SARS-CoV-2 S1-specific IgG antibody levels were measured with EIA in all vaccine combination groups (a 2x BNT162b2, b 2x mRNA-1273, c ChAdOx1 + BNT162b2, d ChAdOx1 + mRNA-1273) from sera collected before vaccination (Pre), three weeks (1D3wk), six weeks (1D6wk) and twelve weeks (1D12wk) after the first vaccine dose (1D), and three weeks (2D3wk), three months (2D3mo), and six months (2D6mo) after the second vaccine dose (2D). The number of samples in each timepoint is presented in Supplementary Table 1. Eight HCWs with PCR confirmed SARS-CoV-2 infection prior to vaccinations are represented with black dots and one HCW with a breakthrough infection (>20 EIA unit increase between samples) after the second vaccine dose is represented with red dots. Geometric mean with geometric SD is represented in figures. Statistical differences between samples collected before vaccination vs. three weeks after the first vaccine dose, between samples collected three vs. twelve weeks after the first dose, between samples collected twelve weeks after the first dose vs. three weeks after the second dose, and between samples collected three weeks after both vaccine doses, were analyzed with two-sided Wilcoxon signed-rank test. P-values <0.05 were considered statistically significant. P-values: <0.0001 marked with ****, 0.0007 with *** and 0.0118 with *, ns indicates not significant. Cut-off values are indicated with dashed lines.

Back to article page